Once a viable API is developed, extensive clinical trials are conducted to evaluate its safety and efficacy in humans. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), require comprehensive data on the API before granting approval for the drug's market release. These regulatory frameworks ensure that only safe and effective medicines reach patients.
One of the most appealing aspects of pentoxifylline is its affordability. Compared to other medications with similar therapeutic effects, pentoxifylline is relatively inexpensive, making it accessible to a broader range of patients. This cost-effectiveness is significant, particularly for those who may be uninsured or underinsured. With rising healthcare costs, the availability of budget-friendly treatment options can significantly alleviate the financial burden on patients and their families.